| Introduction

Minimal Residual Disease (MRD) refers to the retain of minimal amount cancer cells in the stage after a successful treatment of various cancers, which will result in relapse. The detection of MRD in circulating tumour DNA (ctDNA) format samples is limited by sensitivity of current methods and platforms.

To better contribute the development of MRD detecting assays and the promise of precision diagnostics, GeneWell developed a patient sample liked and well characterised MRD ctDNA reference standard set, with gradient allelic frequencies (AFs) as low as 0.005%. It is highly multiplex to cover 37 variants across 25 genes in an identified human geneomic background. The AFs are verified by both digital droplet PCR (ddPCR) and WES, which demonstrates a well consistency among different testing platforms. This MRD set is ideal for the determination of LoD and validation of assay sensitivity. Additionally, it is also an cost-efficiency reference materials to routinely monitor the performance of pan-cancer NGS panels. 

| Key Features

● Derived from  cell line, optimized fragmentation to mimic ctDNA

● 37 hotspot mutations,  covering common genes related to tumor-targeted  therapy

● High consistency between NGS panel and digital PCR 

● Gradient variant  allelic frequency to determine the limit  of detection

| Product List